Argos Therapeutics and Eurofins Lancaster Laboratories (ELL) have received regulatory approval from authorities in the U.S., UK, Canada, Czech Republic and Israel for rapid mycoplasma testing of an autologous cell-based therapy produced by Argos. ELL validated the use of the MilliPROBE system, marketed by EMD Millipore, to test samples of the autologous immunotherapy currently in clinical trials for renal cell carcinoma. The assay can deliver same-day preliminary results compared to 28 days req...